Generation of Tumor-specific T Lymphocytes Using Dendritic Cell/Tumor Fusions and Anti-CD3/CD28
Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), David Avigan(Beth Israel Deaconess Medical Center), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Musie Ghebremichael(Ragon Institute of MGH, MIT and Harvard), Donald Küfe(Dana-Farber Cancer Institute), Baldev Vasir(Beth Israel Deaconess Medical Center), Panagiotis A. Konstantinopoulos(Dana-Farber Cancer Institute), Dimitrios Tzachanis(Dana-Farber Cancer Institute), Corrine Zarwan(Beth Israel Deaconess Medical Center), Dimitrios Spentzos(Beth Israel Deaconess Medical Center), Zekui Wu(Dana-Farber Cancer Institute), Kristen E. Stevenson(Dana-Farber Cancer Institute), Heidi Mills(Beth Israel Deaconess Medical Center), James D. Levine(Beth Israel Deaconess Medical Center), Donna Neuberg(Otsuka (Japan)), Thea M. Friedman(Hackensack University Medical Center), Richard Stone(Dana-Farber Cancer Institute)
Cited by 26
Related Papers
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k